DATROWAY® granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
ENHERTU® granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
ENHERTU® plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
DATROWAY® demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
ENHERTU® reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
ENHERTU® followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
African Discovery Group announces signing of Definitive Sales and Purchase Agreement for Butembo Copper Asset in the Democratic Republic of Congo; name change to Copper Intelligence, Inc
Saga Metals Acknowledges U.S. Strategic Critical Minerals Reserve "Project Vault" and Highlights Titanium's Strategic Importance to North American Defense Supply Chains
Blackrock Silver to Present at the Precious Metals and Critical Minerals Virtual Investor Conference on February 10th 2026
